| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Oct―28 |
DESIGN, SYNTHESIS, AND BINDING ANALYSIS OF TARGET-SPECIFIC COVALENT INHIBITORS OF SARS-CoV-2 PAPAIN-LIKE PROTEASE |
Martynas Bagdonas, Laimonas Stančaitis, Ernestas Urniežius, Audrius Zakšauskas, Aurelija Mickevičiūtė, Rūta Kananavičiūtė, et al. (+7) Audronė Rukšėnaitė, Vaida Juozapaitienė, Jurgita Matulienė, Visvaldas Kairys, Franz-Josef Meyer-Almes, Asta Zubrienė, Daumantas Matulis |
| 2 |
[GO] |
2024―Jun―05 |
Therapeutic potential of natural alkaloid emetine against emerging COVID-19 and future viral pandemics |
Biswanath Dinda, Subhajit Dinda, Manikarna Dinda, Indrajit Sil Sarma, Santanu Majumdar, Shekhar Saha |
| 3 |
[GO] |
2023―Oct―31 |
Clinical implications of a mechanistic link connecting SARS-Cov-2, diabetes mellitus, Zinc in COVID-19 pathophysiology, and the prophylactics in the treatment of SARS-CoV-2 |
Deeptimayee Rout, Atish Kumar Sahoo |
| 4 |
[GO] |
2022―Aug―28 |
Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19 |
Biswanath Dinda, Manikarna Dinda, Subhajit Dinda, Mithun Chakraborty |
| 5 |
[GO] |
2022―Feb―10 |
Investigating Novel Thiazolyl-Indazole Derivatives as Scaffolds for SARS-Cov-2 MPro Inhibitors |
Justin Airas, Catherine A. Bayas, Abdellah N’Ait Ousidi, Moulay Youssef Ait Itto, Aziz Auhmani, Mohamed Loubidi, et al. (+3) M’hamed Esseffar, Julie A. Pollock, Carol A. Parish |
| 6 |
[GO] |
2021―Nov―22 |
Prospective mode of action of Ivermectin: SARS-CoV-2 |
Vaishali M. Patil, Saroj Verma, Neeraj Masand |
| 7 |
[GO] |
2021―Oct―22 |
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment |
Vivek P. Chavda, Normi Gajjar, Nirav Shah, Divyang J. Dave |
| 8 |
[GO] |
2021―Jun―28 |
Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates |
Qian Wang, Zhenming Liu |
|
